What Is Intravesical Therapy and How Is It Used?

Intravesical therapy is the delivery of medication directly into the bladder through a thin catheter inserted via the urethra. By placing drugs right where they are needed, this approach achieves high local concentrations while limiting the rest of the body’s exposure to those drugs. It is most commonly associated with the treatment of non-muscle-invasive bladder cancer, but it also plays a role in managing chronic bladder conditions and recurrent urinary tract infections. The technique sounds straightforward, and in many ways it is, but the details of what gets instilled, when, and for how long vary enormously depending on the condition being treated.

How the Procedure Actually Works

The basic idea is simple. A healthcare provider passes a small, flexible catheter through the urethra into the bladder, drains any urine, and then slowly instills a liquid medication. You typically hold the solution in your bladder for a set period, often one to two hours, before urinating it out. The procedure itself usually takes only a few minutes for the instillation part, though the dwell time adds to the overall appointment. No general anesthesia is needed for most instillations, though some providers use a local numbing gel on the catheter.

The bladder is uniquely suited to this kind of treatment. Its inner lining, the urothelium, forms a remarkably effective barrier. Specialized cells at the surface are joined by tight junctions and covered by both impermeable protein plaques and a mucin layer that resists the absorption of substances from urine into the bloodstream. That barrier is exactly why drugs taken by mouth often struggle to reach the bladder in useful concentrations, and it is the same reason that putting drugs directly inside the bladder keeps them largely contained there, reducing systemic side effects compared to intravenous or oral routes.

This containment is a double-edged sword. The same barrier that protects the body from absorbing the drug also limits how deeply the medication can penetrate into the bladder wall and how long it stays in contact with the tissue. Periodic urination dilutes and flushes the drug away, so treatment schedules typically involve repeated instillations over weeks or months rather than a single session.

Bladder Cancer and the Role of Intravesical Treatment

The dominant use of intravesical therapy is in non-muscle-invasive bladder cancer, often abbreviated NMIBC. This is cancer that has not grown into the deeper muscle layer of the bladder wall. After a surgeon removes visible tumors through a procedure called transurethral resection, microscopic cancer cells can remain on the bladder lining, and those cells frequently seed new tumors. Intravesical therapy exists to reduce that recurrence risk and, in higher-risk cases, to lower the chance of the cancer progressing to a more dangerous stage.

There are two broad categories of intravesical agents used against bladder cancer: chemotherapy drugs and immunotherapy. Each works differently, and the choice between them depends on the risk profile of the tumor.

Single-Dose Chemotherapy After Surgery

For patients with lower-risk tumors, a single instillation of a chemotherapy drug given within hours of tumor removal can meaningfully cut the odds of the cancer coming back. A large prospective trial involving over 2,200 patients found that an immediate instillation of mitomycin C reduced the relative recurrence risk by roughly 27% compared to a delayed instillation. The benefit was strongest in patients with intermediate-risk disease, where recurrence dropped from about 32% to 20% over three years of follow-up.¹

Several chemotherapy drugs can be used for this single post-operative dose. A network meta-analysis comparing different agents found that mitomycin C, epirubicin, and pirarubicin were the most effective at prolonging recurrence-free survival after tumor resection.² Evidence strongly supports the utility of a single early instillation in reducing recurrence for patients with small, low-to-intermediate grade tumors, with relative reduction rates around 35% in that population.³

For intermediate-risk patients who need more than a single dose, extended courses of intravesical chemotherapy with a maintenance schedule appear to offer additional benefit. A systematic review and network meta-analysis found that chemotherapy with a maintenance regimen provided superior protection against five-year recurrence compared to chemotherapy without maintenance in this risk group.⁴

BCG Immunotherapy for High-Risk Disease

For patients whose bladder cancers carry a higher risk of recurrence or progression, the standard intravesical treatment is BCG, which stands for Bacillus Calmette-Guérin. BCG is a live, weakened strain of the bacterium that causes tuberculosis in cattle. When instilled into the bladder, it does not act as a conventional drug that poisons cancer cells. Instead, it provokes a strong local immune response. Research in both animal models and human studies indicates that BCG activates both the innate and adaptive branches of the immune system, ultimately leading to destruction of residual tumor cells on the bladder lining.⁵

BCG treatment is divided into two phases. The induction phase typically involves once-weekly instillations for six weeks. After induction, high-risk patients go on to maintenance therapy, which extends for one to three years or even longer. A widely used maintenance protocol calls for three weekly instillations at specific intervals: three, six, twelve, eighteen, twenty-four, thirty, and thirty-six months after the initial induction course.⁶ Some protocols extend maintenance even further for the highest-risk patients, with dose reductions if side effects become troublesome.⁷

Interestingly, for intermediate-risk patients, BCG does not clearly outperform chemotherapy in terms of preventing recurrence. The network meta-analysis mentioned earlier found no superiority of BCG over chemotherapy for disease recurrence in this group regardless of dose regimen.⁴ This is one reason why BCG is generally reserved for higher-risk disease, where its immune-stimulating properties provide a benefit that chemotherapy alone struggles to match.

Side Effects of BCG and Intravesical Chemotherapy

Intravesical therapy is far gentler on the body than systemic chemotherapy, but it is not side-effect-free. Because you are introducing substances directly into a sensitive organ, local irritation is common.

With BCG, the most frequent problems are bladder irritation, a general feeling of being unwell, and low-grade fever. These reflect the immune activation the treatment is designed to cause. Cystitis, with symptoms like urgency, frequency, and burning during urination, is the most commonly reported adverse effect, occurring in roughly 40% of patients in one large single-center review.⁸ Blood in the urine is also common. Severe complications, such as BCG spreading systemically or causing a serious infection, are rare but do happen. About 8% of patients need to stop BCG treatment altogether because of side effects.⁹

Intravesical chemotherapy drugs like mitomycin C tend to cause less systemic malaise than BCG but can produce their own forms of local irritation, including chemical cystitis and, occasionally, allergic reactions such as a rash on the palms or genitals. Both BCG and chemotherapy carry a high enough risk of side effects that adherence to the full treatment course is a real clinical challenge.¹⁰

The Emotional and Practical Toll

Side effects are not just physical. A systematic review of quality-of-life studies found that BCG instillations significantly affect emotional well-being, contributing to anxiety, depression, and distress, especially during maintenance. Patients described feeling disconnected from their bodies and trapped in a cycle of worry about whether the treatment was working.¹¹ The repetitive nature of the treatment, which can span years, compounds these feelings. A separate study quantifying the practical burden found that employed patients reported roughly 51% work impairment and 59% overall work productivity loss due to their disease and its treatment.¹²

These numbers are striking and help explain why some patients abandon treatment early, even knowing the cancer may return. The tension between long-term oncologic benefit and short-term quality of life is one of the central dilemmas in managing NMIBC, and it drives much of the research into newer, better-tolerated therapies.

When BCG Fails: Salvage Options

BCG does not work for everyone, and in some patients the cancer recurs despite a full course of treatment. Historically, the standard recommendation for these “BCG-unresponsive” patients was radical cystectomy, the surgical removal of the entire bladder. That is a major operation with lifelong consequences for urinary function, and many patients are unwilling or medically unfit to undergo it. This has created strong demand for bladder-sparing intravesical alternatives.

One approach gaining traction is a sequential regimen of intravesical gemcitabine followed by docetaxel, two chemotherapy drugs instilled one after the other in a single session. In a cohort of 102 patients with BCG-unresponsive disease, this combination produced high-grade recurrence-free survival of about 78% at six months, 65% at one year, and 49% at two years, and was well tolerated.¹³ Another institutional series reported roughly 60% progression-free survival at two years with the same regimen, reinforcing its viability as a bladder-sparing option.¹⁴ Longer-term follow-up data show similar high-grade recurrence-free survival rates among BCG-unresponsive patients and the broader cohort, suggesting the benefit holds up over time.¹⁵

Gene Therapy Enters the Bladder

Perhaps the most novel development in intravesical treatment is nadofaragene firadenovec, a gene therapy approved for BCG-unresponsive bladder cancer. Rather than delivering a chemical drug, this treatment delivers a harmless viral vector carrying the gene for interferon alfa-2b directly into the bladder. Bladder cells take up the vector, produce the interferon protein locally, and that protein stimulates an anti-tumor immune response.

In a clinical trial of patients with carcinoma in situ (a flat, high-grade form of bladder cancer), about 53% achieved a complete response within three months of the first dose, and roughly 46% of those initial responders maintained that response at twelve months.¹⁶ Five-year follow-up data from the same trial showed that while long-term high-grade recurrence-free survival remained modest at about 13% for the carcinoma in situ group and 33% for those with papillary tumors, overall survival at five years was 80% and cystectomy-free survival at five years was 49%.¹⁷ Only five patients out of the trial cohort developed progression to muscle-invasive disease. For patients facing the prospect of losing their bladder, those numbers represent a meaningful chance to delay or avoid that surgery.

Beyond Cancer: Interstitial Cystitis and Bladder Pain

Bladder cancer dominates the intravesical therapy landscape, but the same delivery principle applies to other bladder conditions. Interstitial cystitis, also called bladder pain syndrome, is a chronic condition characterized by pelvic pain, urinary urgency, and frequency in the absence of infection. When behavioral changes and oral medications are not enough, intravesical instillation therapy becomes a second-line option. Treatment strategies focus on restoring the protective lining of the bladder, calming overactive nerve signals, and relieving symptoms.¹⁸

A variety of agents have been tried for this purpose, including dimethyl sulfoxide (DMSO), heparin, hyaluronic acid, and lidocaine, often in cocktail combinations. The evidence base for many of these agents is thinner than it is for bladder cancer treatments, and response rates vary widely between individuals. Still, for patients who have exhausted oral options, intravesical instillations can offer relief that systemic drugs cannot.¹⁹

Intravesical Antibiotics for Recurrent Urinary Tract Infections

A newer and still largely off-label use of intravesical therapy involves instilling antibiotics directly into the bladder to treat or prevent recurrent urinary tract infections, particularly in patients who use intermittent catheterization. People with neurogenic bladder conditions or complex urinary tract anatomy often cycle through repeated courses of oral antibiotics, which drives drug resistance and carries systemic side effects. Putting the antibiotic directly into the bladder sidesteps both problems.

Gentamicin is the most studied drug for this purpose. One study found that intravesical gentamicin reduced the average number of UTIs from about 4.8 per treatment period to 1.0, and the proportion of drug-resistant bacteria in urine cultures dropped from 78% to 23%. No systemic absorption or clinically relevant side effects were observed.²⁰ Similar findings have been reported in both adult and pediatric populations with complex bladder conditions.²¹ A review of the available literature concluded that intravesical gentamicin appears safe and effective as an alternative when systemic treatments have failed, though it remains off-label.²²

Botulinum Toxin Injections Into the Bladder Wall

Intravesical therapy does not always mean passively instilling a liquid. Botulinum toxin A, commonly known by its brand names, is injected directly into the bladder muscle during a cystoscopy procedure. This is technically an intravesical intervention, though the delivery method is different from a standard instillation.

Botulinum toxin works by blocking the nerve signals that cause the bladder muscle to contract involuntarily. It has proven effective at reducing bladder pressure and incontinence episodes in patients with neurogenic bladder dysfunction, where nerve damage from conditions like spinal cord injury or multiple sclerosis causes uncontrolled bladder contractions.²³ It also benefits patients with overactive bladder who cannot tolerate or do not respond to oral medications.²⁴ The effect is temporary, lasting several months before repeat injections are needed, but for many patients it provides a level of bladder control that oral drugs alone cannot achieve.

Why the Bladder Is a Difficult Drug Target

For all its advantages, intravesical therapy is constrained by the bladder’s own biology. The urothelium’s barrier, made up of umbrella cells with tight junctions, impermeable surface plaques, and a mucin coating, prevents most molecules from penetrating deeply into the bladder wall.²⁵ And because the bladder fills and empties every few hours, drug contact time is inherently limited. Most instilled solutions are significantly diluted by incoming urine within an hour or two of placement.

Researchers have pursued several strategies to overcome these obstacles. Heating the instilled solution, a technique known as hyperthermic intravesical chemotherapy, is one approach. A study from a high-volume center using heated chemotherapy reported one-year recurrence-free survival of 67% and two-year recurrence-free survival of 40%, with progression to muscle invasion in only one of sixty patients.²⁶ Other strategies under investigation include mucoadhesive drug carriers that stick to the bladder wall, slow-release implantable devices, and nanoparticle formulations designed to cross the urothelial barrier more effectively.²⁷ The field is also exploring intravesical pumps that could deliver medication continuously from within the bladder, which would be particularly useful for non-cancer conditions like overactive bladder, where patients who cannot tolerate oral anticholinergic drugs currently have limited nonsurgical options.²⁸

Safety during the instillation process itself has also received attention. Chemotherapy drugs are hazardous materials, and spills during catheter handling pose a risk to healthcare workers. A quality improvement project at a large healthcare system in Los Angeles found that after implementing standardized catheter clamping procedures and appropriate protective equipment, chemotherapy spills during intravesical treatment were eliminated across four surgical locations.²⁹ These logistical details may seem mundane, but they matter for the thousands of healthcare workers who handle these treatments daily.